Follow our progress.

Milestones in our journey to reinvent genetic testing.

Press Releases

Invitae to announce second quarter 2015 financial results and host conference call on August 6, 2015

Invitae to announce second quarter 2015 financial results and host conference call on August 6, 2015

July 23, 2015

SAN FRANCISCO Invitae Corporation (NYSE: NVTA), a genetic information company, today announced that it will report its second quarter 2015 financial results on Thursday, August 6, 2015 and will host a conference call that day at 4:45 p.m. ET/1:45 p.m. PT to discuss the financial results and recent developments.

The dial-in numbers for the conference call are (877) 201-0168 for domestic callers and (647) 788-4901 for international callers, and the reservation number for both ...

Read more


Invitae announces online publication of data comparing traditional and multi-gene panel testing for hereditary breast and ovarian cancer in The Journal of Molecular Diagnostics

Invitae announces online publication of data comparing traditional and multi-gene panel testing for hereditary breast and ovarian cancer in The Journal of Molecular Diagnostics

July 22, 2015

SAN FRANCISCO – Invitae Corporation (NYSE: NVTA), a genetic information company, and collaborators announced the publication of data directly comparing traditional and multi-gene panel testing in more than 1,000 patients in The Journal of Molecular Diagnostics. The data, published online today, are from a collaboration among Invitae, Massachusetts General Hospital, Harvard Medical School, and the Stanford University School of Medicine. The Journal of Molecular Diagnostics is the official journal of the Association for Molecular Pathology, the society of professionals ...

Read more


Invitae launches new patient pay price of $475 for its full menu of genetic tests

Invitae launches new patient pay price of $475 for its full menu of genetic tests

June 01, 2015

Company’s goal is to make genetic testing more affordable and accessible

Applies to full menu of testing in cancer, cardiology, neurology, pediatric genetics, hematology and other rare conditions

SAN FRANCISCO, June 1, 2015 – Invitae Corporation (NYSE: NVTA), a genetic information company, announced today the launch of its new patient pay price for its full menu of genetic tests at $475 per indication. This new price covers all of Invitae’s offerings in cancer, cardiology, neurology, pediatric genetics, hematology and other ...

Read more


Invitae and collaborators to present new data at the 2015 American Society of Clinical Oncology Annual Meeting focusing on the clinical utility of multi-gene panel tests for hereditary breast and ovarian cancer

Invitae and collaborators to present new data at the 2015 American Society of Clinical Oncology Annual Meeting focusing on the clinical utility of multi-gene panel tests for hereditary breast and ovarian cancer

May 13, 2015

Study demonstrates that Invitae's multi-gene test yields clinically actionable findings for substantially more patients than does traditional single-gene testing

SAN FRANCISCO – Invitae Corporation (NYSE: NVTA), a genetic information company, announced that new data will be presented during the 51st American Society of Clinical Oncology (ASCO) Annual Meeting. The presentation, “Clinical Impact of Multi-Gene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment” (Abstract 1513), will be presented as a poster discussion on Monday, June 1 by Leif W. Ellisen ...

Read more


Charcot-Marie-Tooth Association announces educational sponsorship with Invitae

Charcot-Marie-Tooth Association announces educational sponsorship with Invitae

May 13, 2015

Organizations teaming up to increase awareness, improve public education for one of the most common neurological conditions

GLENOLDEN, Pa. and SAN FRANCISCO – The Charcot-Marie-Tooth Association (CMTA) announced today that it has formed an educational sponsorship with Invitae Corporation, a genetic information company. 

Affecting nearly 3 million people worldwide, Charcot-Marie-Tooth (CMT) is a group of inherited disorders that affect the peripheral nerves, which are the nerves outside the brain and spinal cord. There are more than 80 kinds of CMT ...

Read more


Invitae announces first quarter 2015 financial results and highlights

Invitae announces first quarter 2015 financial results and highlights

May 12, 2015

Company accelerates R&D and reports strong volume growth
Announces new pricing programs to make genetic testing more affordable and accessible

SAN FRANCISCO – Invitae Corporation (NYSE: NVTA) today reported financial and operating results for the first quarter ended March 31, 2015. Highlights for the quarter include:

  • Generated revenue of $1.2 million in the first quarter, an increase of 40% over revenue in the fourth quarter of 2014.
  • Increased volume by delivering more than 2,200 billable reports, an increase ...

Read more


Invitae to announce first quarter 2015 financial results and host conference call May 12, 2015

Invitae to announce first quarter 2015 financial results and host conference call May 12, 2015

April 28, 2015

SAN FRANCISCO – Invitae Corporation (NYSE: NVTA), a genetic information company, today announced that it will report its first quarter 2015 financial results on Tuesday, May 12, 2015. Invitae’s management team will host a conference call on Tuesday, May 12, 2015 at 4:45 p.m. ET/1:45 p.m. PT to discuss the financial results and recent developments.

The dial-in numbers for the conference call are (877) 201-0168 for domestic callers and (647) 788-4901 for international callers, and ...

Read more


Invitae appoints Robert Nussbaum, M.D. as Chief Medical Officer

Invitae appoints Robert Nussbaum, M.D. as Chief Medical Officer

April 27, 2015

Medical genetics pioneer from UCSF to join executive team to lead medical organization

SAN FRANCISCO – Invitae Corporation (NYSE: NVTA), a genetic information company, today announced the appointment of Robert L. Nussbaum, M.D. as Chief Medical Officer; such appointment will become effective August 1, 2015. As a board-certified internist and medical geneticist, Dr. Nussbaum has dedicated his career to improving the care of adults and children with hereditary disorders.

Dr. Nussbaum was most recently chief of the Division of ...

Read more


Invitae presents new data demonstrating use of next-generation sequencing for multi-gene panels at the 2015 American College of Medical Genetics Annual Clinical Genetics Meeting

Invitae presents new data demonstrating use of next-generation sequencing for multi-gene panels at the 2015 American College of Medical Genetics Annual Clinical Genetics Meeting

March 26, 2015

Company also expands test catalog; now offers full coverage of CHEK2 gene and four new cancer-related genes

SALT LAKE CITY and SAN FRANCISCO – Invitae Corporation (NYSE: NVTA), a genetic information company, is presenting seven posters at the 2015 American College of Medical Genetics (ACMG) Annual Clinical Genetics Meeting, including data demonstrating the use of next-generation sequencing (NGS) technology in genetic testing, a proposed variant classification system based on ACMG guidelines and genetic testing case studies.

Invitae also announced that ...

Read more


Invitae to present seven posters highlighting new data on the use of next-generation sequencing for multi-gene panels at the 2015 American College of Medical Genetics Annual Clinical Genetics Meeting

Invitae to present seven posters highlighting new data on the use of next-generation sequencing for multi-gene panels at the 2015 American College of Medical Genetics Annual Clinical Genetics Meeting

March 17, 2015

SAN FRANCISCO – Invitae Corporation (NYSE: NVTA), a genetic information company, today announced it will be presenting seven posters at the 2015 American College of Medical Genetics (ACMG) Annual Clinical Genetics Meeting in Salt Lake City. 

The titles and schedule of the poster presentations are as follows:

Poster Session 1: Thursday, March 26, 10:30 am – 12:00 pm MT

  • Poster #105: Next-Generation Panel vs. Traditional BRCA1/2 Testing: Challenging Variants, Classification Under the Draft ACMG ISV Guidelines and Potential ...

Read more